IDEAYA Biosciences, Inc. (BST:30J)
| Market Cap | 2.25B -10.7% |
| Revenue (ttm) | 32.17M -83.0% |
| Net Income | -369.86M |
| EPS | -4.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283 |
| Open | 23.55 |
| Previous Close | 23.87 |
| Day's Range | 23.07 - 23.84 |
| 52-Week Range | 23.23 - 36.46 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Feb 12, 2027 |
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ideaya Biosciences price target lowered to $55 from $62 at JPMorgan
JPMorgan lowered the firm’s price target on Ideaya Biosciences (IDYA) to $55 from $62 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first…
Ideaya Biosciences falls -11.8%
Ideaya Biosciences (IDYA) is down -11.8%, or -$3.57 to $26.79.
IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference
Darovasertib's NDA acceptance is anticipated this quarter, with a potential H1-next-year launch and OS interim analysis projected for mid-next year. IDE849 studies and pipeline combination programs provide additional catalysts through 2027.
Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849
Ideaya announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 – DLL3-targeting Topo-I-payload antibody drug conjugate, or ADC, in previously treated neuroendoc...
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple ref...
IDEAYA Biosciences Transcript: R&D Day 2026
The pipeline spans PRMT5, KAT6/7, and CDKN2A programs, with early clinical signals and combination strategies targeting tumor drivers and resistance. Multiple IDE892 and IDE574 updates are planned for 2027, while IDE101 combination data may follow in 2028.
IDEAYA Biosciences Slides: FY 2026
IDEAYA Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 16, 2026.
IDEAYA Biosciences Transcript: UBS Global Biopharma Conference 2026
The darovasertib NDA was filed under RTOR with a strategy seeking HLA-A2-independent use; PFS was viewed as sufficient for accelerated approval, with interim OS guided for mid-2027. PRMT5 combination data were targeted for 2027, while DLL3 Phase III trials were planned to start by year-end 2026.
Ideaya Biosciences announces development candidate nomination of IDE101
IDEAYA Biosciences (IDYA) announced development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase, CDK, inhibitor designed to address the loss of CDKN2A-mediated ...
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietar...
Ideaya Biosciences price target lowered to $39 from $44 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $39 from $44 and keeps an Outperform rating on the shares following the Q3 report.
Ideaya Biosciences price target raised to $66 from $65 at Citi
Citi raised the firm’s price target on Ideaya Biosciences (IDYA) to $66 from $65 and keeps a Buy rating on the shares.
Ideaya Biosciences price target lowered to $45 from $48 at RBC Capital
RBC Capital lowered the firm’s price target on Ideaya Biosciences (IDYA) to $45 from $48 and keeps an Outperform rating on the shares after its Q3 results. All programs continue…
Ideaya Biosciences price target raised to $63 from $60 at Wedbush
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $63 from $60 and keeps an Outperform rating on the shares. The firm notes the company reported third quarter…
Ideaya Biosciences price target lowered to $52 from $57 at Guggenheim
Guggenheim lowered the firm’s price target on Ideaya Biosciences (IDYA) to $52 from $57 and keeps a Buy rating on the shares.
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
Ideaya Biosciences price target lowered to $57 from $59 at Truist
Truist lowered the firm’s price target on Ideaya Biosciences (IDYA) to $57 from $59 and keeps a Buy rating on the shares. The company’s Q3 and the firm’s 1×1 with…
Ideaya Biosciences reports Q3 EPS ($1.22), consensus ($1.16)
Reports Q3 revenue $10.24M, consensus $7.58M. “We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for…
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disea...
IDEAYA Biosciences Earnings release: Q3 2026
IDEAYA Biosciences released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
IDEAYA Biosciences Quarterly report: Q3 2026
IDEAYA Biosciences has published its Q3 2026 quarterly earnings report on November 3, 2026.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization ...
Ideaya Biosciences price target lowered to $44 from $50 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $44 from $50 and keeps an Outperform rating on the shares.
Ideaya Biosciences announces updated clinical results from IDE849 trial
Ideaya Biosciences (IDYA) announced updated clinical results that show anti-tumor activity and preliminary overall survival results for IDE849, its investigational antibody-drug conjugate, or ADC, dir...
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55...